Sonnet: Sonnet BioTherapeutics Selected for Poster Presentation at the 2025 AACR IO Conference

PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the "Company" or "Sonnet") (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced its abstract has been accepted for poster presentation at the 2025 American Association for Cancer Research (AACR) IO Conference taking place on February 23-26, 2025 at the JW Marriott in Los Angeles, CA.Details of the poster presentation are as follows:Session: Poster Session BAbstract title: Combination immunotherapy with an albumin-binding interleukin-12 fusion protein that extends cytokine half-life, targets the tumor microenvironment, and enhances therapeutic efficacySession Date and Time: Tuesday, February 25, 2025 from 1:45-4:45 PM PTFor more information about the conference, please visit the event website.About Sonnet BioTherapeutics Holdings, Inc.Sonnet is an oncology-focused biotechnology company with a proprietary platform for developing targeted biologic drugs with single or bifunctional action. Known as FHAB (Fully Human Albumin-Binding), the technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to target tissues. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for optimizing the ...Full story available on Benzinga.com